<DOC>
	<DOC>NCT00923156</DOC>
	<brief_summary>In addition to the blood pressure lowering effects of aliskiren, it may have beneficial effects on blocking the so called RAAS (renin-angiotensin-aldosterone system) at the tissue level. An increase of angiotensin II is associated with progression of heart failure. Although the use of ACE-inhibitors in heart failure shows clinical benefit, an increase in angiotensin II due to an angiotensin II "escape" phenomenon is not desirable. It is not yet known if a direct renin inhibitor can reduce or even prevent the angiotensin II escape phenomenon associated with the use of an ACE-inhibitor. Therefore the study tested the effects of ramipril, aliskiren and the combination of both on levels of angiotensin II in the blood in patients with systolic heart failure</brief_summary>
	<brief_title>Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure, Systolic</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<criteria>Decompensated systolic heart failure, left ventricular ejection fraction ≤40% Brain natriuretic peptide (BNP) level ≥ 100 pg/mL Exclusion criteria: Use of Angiotensin Converting Enzyme(ACE) or Angiotensin Receptor Blocker (ARB) inhibitor treatment following the runin period or requirement of both treatments Acute heart failure secondary to acute myocardial infarction, acute coronary syndrome or new tachyarrhythmia Occurrence of unstable angina or myocardial infarction within 12 weeks prior to screening History of cardiomyopathy such as postpartum, restrictive, infective, hypertrophic obstructive History of right heart failure due to pulmonary disease History of untreated second or third degree atrioventricular heart block Other protocoldefined inclusion/exclusion criteria applied</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Systolic</keyword>
	<keyword>Aliskiren</keyword>
	<keyword>Ramipril</keyword>
	<keyword>Angiotensin II</keyword>
	<keyword>Ang II</keyword>
	<keyword>Plasma Renin Activity</keyword>
	<keyword>PRA</keyword>
	<keyword>Plasma Renin Concentration</keyword>
	<keyword>PR,</keyword>
	<keyword>brain natriuretic peptide</keyword>
	<keyword>BNP</keyword>
	<keyword>urinary aldosterone</keyword>
	<keyword>Escape</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>PK</keyword>
</DOC>